The Journal of invasive cardiology · 2026
Access to atrial flow regulators for implantation in critically ill children via the US Food and Drug Administration's emergency use pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iskander Christopher, Kucuk Mehmet, Taylor Anne, Leahy Ryan, Zablah Jenny E, Morgan Gareth J
Аннотация
OBJECTIVES: The authors conducted a review of the US Food and Drug Administration's (FDA) emergency use authorization (EUA) pathway as a mechanism to use the Occlutech Atrial Flow Regulator (AFR) (Occlutech International AB) for critically ill pediatric patients with congenital heart disease.
METHODS: The authors describe 8 pediatric patients in whom the EUA pathway was activated to permit AFR implantation and provide potentially lifesaving therapy.
RESULTS: Emergency authorization was granted for each of the 8 cases with successful implantation of the AFR. There were 2 cases in which the patient required a repeat catheterization for thrombus on the device, but all 8 patients were able to progress their care. These cases demonstrate the feasibility of the EUA pathway to access emerging technologies for pediatric patients.
CONCLUSIONS: The Occlutech AFR may provide an important therapeutic option for critically ill children with congenital heart disease. The EUA pathway can facilitate timely access to unapproved but potentially beneficial technologies when no satisfactory approved alternatives exist.
METHODS: The authors describe 8 pediatric patients in whom the EUA pathway was activated to permit AFR implantation and provide potentially lifesaving therapy.
RESULTS: Emergency authorization was granted for each of the 8 cases with successful implantation of the AFR. There were 2 cases in which the patient required a repeat catheterization for thrombus on the device, but all 8 patients were able to progress their care. These cases demonstrate the feasibility of the EUA pathway to access emerging technologies for pediatric patients.
CONCLUSIONS: The Occlutech AFR may provide an important therapeutic option for critically ill children with congenital heart disease. The EUA pathway can facilitate timely access to unapproved but potentially beneficial technologies when no satisfactory approved alternatives exist.